- Home
- GRCE vs CCEL Comparison
GRCE vs CCEL Comparison
Compare GRCE & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- CCEL
- Stock Information
- Founded
- GRCE 2002
- CCEL 1989
- Country
- GRCE United States
- CCEL United States
- Employees
- GRCE N/A
- CCEL N/A
- Industry
- GRCE
- CCEL Managed Health Care
- Sector
- GRCE
- CCEL Health Care
- Exchange
- GRCE NYSE
- CCEL Nasdaq
- Market Cap
- GRCE 42.4M
- CCEL 39.9M
- IPO Year
- GRCE N/A
- CCEL 1997
- Fundamental
- Price
- GRCE $3.08
- CCEL $5.00
- Analyst Decision
- GRCE Strong Buy
- CCEL Strong Buy
- Analyst Count
- GRCE 1
- CCEL 1
- Target Price
- GRCE $12.00
- CCEL $8.50
- AVG Volume (30 Days)
- GRCE 62.2K
- CCEL 8.8K
- Earning Date
- GRCE 08-15-2025
- CCEL 07-15-2025
- Dividend Yield
- GRCE N/A
- CCEL 11.99%
- EPS Growth
- GRCE N/A
- CCEL N/A
- EPS
- GRCE N/A
- CCEL N/A
- Revenue
- GRCE N/A
- CCEL $31,988,783.00
- Revenue This Year
- GRCE N/A
- CCEL $2.49
- Revenue Next Year
- GRCE N/A
- CCEL $0.95
- P/E Ratio
- GRCE N/A
- CCEL N/A
- Revenue Growth
- GRCE N/A
- CCEL 1.10
- 52 Week Low
- GRCE $1.75
- CCEL $4.68
- 52 Week High
- GRCE $4.97
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- CCEL 50.57
- Support Level
- GRCE N/A
- CCEL $4.82
- Resistance Level
- GRCE N/A
- CCEL $5.30
- Average True Range (ATR)
- GRCE 0.00
- CCEL 0.25
- MACD
- GRCE 0.00
- CCEL 0.01
- Stochastic Oscillator
- GRCE 0.00
- CCEL 51.98
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.